

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The products are primarily used at emergency departments in hospitals for risk stratification of acute medical patients to improve clinical decisions on discharge and hospitalization.

ViroGates' suPARnostic® product range measures the protein, suPAR (soluble urokinase Plasminogen Activator Receptor). The protein is naturally occurring in human blood and reflects the immune system's activation level. A patient's suPAR level predicts negative outcomes such as short-term mortality across acute and chronic diseases. The suPARnostic® tests are easily integrated into existing hospital workflows and instruments, and the results are available in 10-20 minutes.

The company was founded in 2000 based on the discovery that suPAR was predictive of the outcome in HIV infections and subsequently in many other disease areas. Headquartered in Birkerød, Denmark, ViroGates' sales force covers the Nordics, Spain, and France, while distributors serve other markets.

ViroGates' shares (VIRO) have been listed on Nasdaq First North Growth Market Denmark since 2018.

● ViroGates




Share Data		24/05/2022
Previous Close		75.40
Change (%)		-0.26
Volume		103
Number of Shares		3,170,083
Market Cap		239.02

KEY FIGURES - DKK('000)	2021	2020
Income statement		
Net revenue	7,656	5,354
Operating profit/loss	-18,790	-19,729
Profit/loss for the year	-17,663	-18,736
Balance sheet		
Balance sheet total	20,229	38,246
Equity	16,426	31,314
Invested capital	4,815	895
Cash flows		
Cash flows from operating activities	-21,437	-15,602
Cash flows from investment related activities	-4	-114
Cash flows from financing activities	2,776	7,835
Total cash flows	-18,665	-7,881
Cash and cash equivalents	14,859	33,526
Ratios		
Rate of return	-658.2	-1,028.1
Number of employees, end of period	13	14
Market share price, end of period (DKK)	144.0	81.5


MAJOR SHAREHOLDERS

At the end of 2021, ViroGates had 1,621 registered shareholders. Three shareholders had notified shareholdings of 5% or more:

Shareholders (31/12/2021)	Number Of Shares	Percent Of Capital
N. P. Louis-Hansen ApS	817,075	25.77%
Ginnerup Capital ApS	325,965	10.28%
4AM ApS	325,965	10.28%



Sales by product (2021)



* Other includes analysis services, freight and handling